EN DE
Watch UMediC Group Berhad for free: we tell you when fair value or trend changes.
Data-driven stock valuation

UMediC Group Berhad (0256) fair value: what the stock is really worth

As of Nov 6, 2026: fair value (intrinsic value) of UMediC Group Berhad stock MYR 0.45, price MYR 0.27, upside +69.8%, quality 47 out of 100. Rating: strongly undervalued. Calculated from audited financials with 16 of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare MY · ISIN MYQ0256OO006

UG UMediC Group Berhad logo Thin data Nov 4, 2026

UMediC Group Berhad

0256 · KLSE
Cheap, value-trap risk

The stock costs 41% less than our calculation considers fair.

Fair value 0.4500 MYR · Strongly undervalued
Solidly profitable · 13.2% net margin (TTM)
Low debt
Ranks above peers (11/13)
Revenue last quarter +52% vs. a year ago.
Quality 47/100
Expensive Growth (revenue 5y +11.5 %/yr in MYR)
1.1% dividend yield · Watch coverage
Moderate moat 53/100 · thin data
Negative free cash flow
Thin data
Watch UMediC Group Berhad for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

0.8814 MYR 0.2550 MYR Fair Value 0.4500 MYR Jul 2022 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 4, 2026.

How to read this chart

51‑month range 0.2550 MYR – 0.8814 MYR · fair‑value band 0.3100 MYR – 0.5700 MYR · the 0.2650 MYR price screens below the 0.4500 MYR fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 4, 2026.

Follow UMediC Group Berhad in your weekly email

Every Wednesday you see whether UMediC Group Berhad is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

UMediC Group Berhad, an investment holding company, develops, manufactures, markets, and distributes medical devices and consumables in Malaysia, the Asia Pacific, the Americas, Europe, the Middle East, Africa, and Oceania.

Show moreShow less

The company operates nursing homes and healthcare centers, and other related services; markets and distributes laboratory equipment and consumables; and provides after-sales services.

It also provides HYDROX prefilled humidifiers and nebulizers; AIRDROX inhaler spacers; FLEXIDROX water for inhalation bag; and hospital furniture, life-support solution, MR compatible monitoring solution, oxygen therapy and suction solution, patient monitoring system, resuscitation care, ultrasound solution, women and childcare, critical care solution, and anaesthesia solution.

In addition, the company offers various services, including clinical training on equipment, planned preventive maintenance, installations, equipment pre-checks, equipment servicing and repair, 24/7 emergency call-out, unlimited break down call, and spare parts procurement.

The company was formerly known as UMediC Group Sdn Bhd and changed its name to UMediC Group Berhad in September 2021. UMediC Group Berhad was incorporated in 2021 and is headquartered in Penang, Malaysia. UMediC Group Berhad is a subsidiary of UMediC Capital Sdn Bhd.

Stock analysis

UMediC Group Berhad (0256) currently trades at 0.2650 MYR, while our model-based Fair Value estimate is 0.4500 MYR, implying the stock looks roughly 41% undervalued today.

Show more

Valuation

Bull case: the Growth Earnings group reads highest at a median of 0.4500 MYR per share, and 10 of the 16 models we run sit above the 0.2650 MYR price.

Bear case: the Asset-Based group reads lowest at 0.1100 MYR, and 6 of the 16 models stay below the price. Data coverage for this calculation is low.

Scenario range: 0.3100 MYR (bear) to 0.5700 MYR (bull), the price of 0.2650 MYR sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 47/100 (below-average quality), in the Healthcare sector.

Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.

UMediC Group Berhad reported revenue of 58.7M MYR in FY2026 versus 50.7M MYR in FY2022, a compound +3.7%/yr. Reported net income was 7.7M MYR in FY2026, compounding +4.7%/yr from FY2022.

Key figures

Market cap 99.1M MYR (≈ $24.4M) Micro · P/E ratio 12.9 · P/S ratio 1.69 · EPS (TTM) 0.0206 MYR · Dividend yield 1.1% · Net margin 13.2% · Return on equity 9.6% · Return on assets (EBIT) 12.1% (5-year average).

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 53 out of 100 (low confidence).

What moves the price

The share trades about 35% below its 52-week high and 4% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −15% fair-value upside, at 70%, 0256 screens cheaper than that median.

Fair Value models

Bear 0.3100 MYR Fair Value 0.4500 MYR Bull 0.5700 MYR
Price 0.2650 MYR · Upside +69.8%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2026 figures (about 3 months old). Earnings retained since then (0.0047 MYR per share) are deliberately not added. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
Residual Income 0.1900 MYR 0.2100 MYR 0.2400 MYR 76
ROIC Compounder 0.1900 MYR 0.2100 MYR 0.2400 MYR 72
EPV 0.1900 MYR 0.2100 MYR 0.2300 MYR 71
All 16 models by family
Earnings-Based
Graham-Dodd 0.1400 MYR 0.7500 MYR 1.04 MYR 63
Lynch FV 0.2100 MYR 0.3000 MYR 0.3900 MYR 61
PEG = 1.0 0.2100 MYR 0.3000 MYR 0.3900 MYR 57
EPV 0.1900 MYR 0.2100 MYR 0.2300 MYR 71
Dividend Discount
Gordon GGM 0.0300 MYR 0.0500 MYR 0.0800 MYR 67
DDM Multi-Stage 0.0300 MYR 0.0400 MYR 0.0500 MYR 67
Multiples
P/E Multiple 0.3400 MYR 0.4500 MYR 0.5700 MYR 63
P/S Multiple 0.2600 MYR 0.3500 MYR 0.4400 MYR 58
P/B Multiple 0.5700 MYR 0.7600 MYR 0.9600 MYR 55
EV/EBIT 0.3000 MYR 0.4000 MYR 0.5000 MYR 66
EV/EBITDA 0.3600 MYR 0.4800 MYR 0.5900 MYR 67
EV/Revenue 0.2100 MYR 0.3100 MYR 0.4000 MYR 53
Asset-Based
NCAV (Graham) 0.0700 MYR 0.1100 MYR 0.1400 MYR 54
Economic Profit
Residual Income 0.1900 MYR 0.2100 MYR 0.2400 MYR 76
ROIC Compounder 0.1900 MYR 0.2100 MYR 0.2400 MYR 72
Growth Earnings
Growth-Adj P/E 0.3100 MYR 0.4500 MYR 0.5800 MYR 67

Open the full fair value analysis →

Quality Score breakdown

Overall quality 47/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 45
How much profit the company makes from its sales and capital
Quality Growth 39
Are margins and returns getting better?
Cashflow 0
Do the profits arrive as real cash?
Financial strength 84
Debt, balance sheet and risk of trouble
Investment 30
Does it invest with discipline instead of growing at any price?
Low Volatility 70
How calm the share price moves, does not count
Price momentum 16
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 3
Distance to the 52-week high, does not count
New shares 82
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 57/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+20.8%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+8.9%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+11.5%
Start year 2021 (pandemic)
Revenue growth 6 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+16.3%
What shareholders gained per year (last 5 years), in MYR ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in MYR: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
+9.8%
Earnings growth per share plus dividend.
Earnings per share, growth per year+8.7%
Dividend (yield on the price)1.1%
Profit margin 2021 to 2026 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.20% → 15%

Watch 0256, get fair value alerts →

Compare UMediC Group Berhad with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Devices · 318 stocks

Beats the industry median on 11/13 measures
Overall it ranks above its industry peers.
Valuation
Quality Score 47 · Below median
Fair Value upside +69.8% · Top 25%
Profitability
Return on equity (12 months) 9.6% · Above median
Return on assets 7.1% · Top 25%
Net margin (12 months) 13.2% · Above median
Operating margin (12 months) 14.3% · Above median
Growth and dividend
Revenue growth (quarter YoY) 52.0% · Top 25%
Dividend yield (12 months) 1.1% · Below median
Balance sheet
Debt / equity 0.04× · Below median

Valuation Multiplesvs Medical Devices median · lower = cheaper

P/E (12 months) 12.9× · Cheapest 25%
P/B 1.14× · Cheaper than median
P/S (12 months) 1.69× · Cheaper than median
EV/EBITDA 7.4× · Cheapest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)100 · sector 6
FUTURE (revenue growth)100 · sector 36
PAST (return on equity)38 · sector 17
HEALTH (low debt)98 · sector 98
DIVIDEND (yield)23 · sector 34

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Devices stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Stryker Corporation SYK $325.87 $358.46 +10% vs 0256
Boston Scientific Corporation BSX $42.75 $47.03 +10% vs 0256
Shenzhen Mindray Bio-Medical Electronics Co 300760 ¥184.15 ¥202.57 +10% vs 0256
DexCom, Inc DXCM $79.41 $87.35 +10% vs 0256
GE HealthCare Technologies Inc GEHC $82.38 $69.92 −15% vs 0256
Edwards Lifesciences Corporation EW $102.14 $81.94 −20% vs 0256
Siemens Healthineers AG SHL €44.66 €34.51 −23% vs 0256
Abbott Laboratories, ABT $109.93 $75.28 −32% vs 0256
Medtronic plc MDT $101.80 $65.61 −36% vs 0256
Koninklijke Philips N.V PHIA €27.33 €15.23 −44% vs 0256

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

UMediC Group Berhad: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "UMediC Group Berhad Fair Value". https://www.fairvalue-calculator.com/stock/0256

Frequently asked questions

Is UMediC Group Berhad (0256) overvalued or undervalued?
As of Nov 4, 2026, our model estimates a fair value of 0.4500 MYR versus a price of 0.2650 MYR, about +70% upside (undervalued).
What is the fair value of 0256?
Our model-based fair value for UMediC Group Berhad is 0.4500 MYR (as of Nov 4, 2026), built from audited fundamentals. The current price: 0.2650 MYR.
What is the quality score of 0256?
UMediC Group Berhad has a Quality Score of 47/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for UMediC Group Berhad (0256)?
Our model-based price target is the fair value of 0.4500 MYR (as of Nov 4, 2026) from 16 valuation models. Cautious scenario 0.3100 MYR, optimistic scenario 0.5700 MYR. It is a calculation from audited fundamentals, not an analyst target.
What is the UMediC Group Berhad stock forecast for 2026?
Our models put fair value at 0.4500 MYR, about +70% upside versus a price of 0.2650 MYR (undervalued). Cautious scenario 0.3100 MYR, optimistic scenario 0.5700 MYR. The calculation is refreshed regularly with new filings.
What is the revenue of UMediC Group Berhad (0256)?
UMediC Group Berhad reported trailing-twelve-month revenue of about 58.7M MYR (latest available figure, as of Nov 4, 2026).
Does UMediC Group Berhad pay a dividend?
UMediC Group Berhad currently shows a dividend yield of 1.13% relative to its recent price (as of Nov 4, 2026).
How much is the dividend of UMediC Group Berhad (0256) and when is the ex-dividend date?
UMediC Group Berhad pays a dividend of 0.003 MYR per share a year, a dividend yield of 1.1%. The last ex-dividend date was Jan 29, 2026. The payout ratio is 15.0% of earnings. Our assessment: Watch coverage. The dividend isn’t fully covered by free cash flow or earnings, part of it is funded from reserves or debt. Fine for now, but worth watching: if it stays uncovered, the dividend could be cut.
What is the intrinsic value of UMediC Group Berhad (0256)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For UMediC Group Berhad it is 0.4500 MYR per share (as of Nov 4, 2026), against a price of 0.2650 MYR. It is the blended result of 16 valuation models in 6 families (Earnings-Based, Dividend Discount, Multiples, Asset-Based, Economic Profit, Growth Earnings).
Is UMediC Group Berhad stock overvalued or undervalued in 2026?
As of Nov 4, 2026, 0256 trades below its calculated fair value: price 0.2650 MYR, fair value 0.4500 MYR, a gap of about +70% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 0256?
No. The price is what the market pays today (0.2650 MYR); the fair value is what the company's own numbers justify (0.4500 MYR). For UMediC Group Berhad the two are 0.1850 MYR per share apart. That gap is exactly why we show both numbers side by side.
How much is UMediC Group Berhad worth?
The market values UMediC Group Berhad at about 99.1M MYR (market capitalisation, as of Nov 4, 2026). Per share that is 0.2650 MYR; our models calculate a fair value of 0.4500 MYR per share.
What do the bullish and bearish scenarios say about 0256?
Our models span a range for UMediC Group Berhad: cautious scenario 0.3100 MYR, base 0.4500 MYR, optimistic 0.5700 MYR per share (as of Nov 4, 2026, price 0.2650 MYR). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 0256?
UMediC Group Berhad trades at a price-to-earnings ratio of 12.9 (as of Nov 4, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of 0.4500 MYR is built from several models across several years. Median P/E at fiscal year-end, 5 fiscal years (2022 to 2026), reported earnings, FY2026 ex one-offs: 25.6. Other multiples: P/B 1.1, P/S 1.7, EV/EBITDA 7.4.
How solid is the balance sheet of UMediC Group Berhad (0256)?
Balance-sheet figures for UMediC Group Berhad (as of Nov 4, 2026): return on equity 9.6%, debt of 0.04 per unit of equity. They feed the Quality Score of 47/100, which measures business quality independently of the share price.
How far is 0256 from its 52-week high?
UMediC Group Berhad trades at 0.2650 MYR, about 35% below its 52-week high of 0.4060 MYR and 4% above the low of 0.2550 MYR (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of 0.4500 MYR is for.
Which stocks are comparable to UMediC Group Berhad?
From the same area (Healthcare) we also value Abbott Laboratories,, Medtronic plc, Stryker Corporation, Boston Scientific Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is UMediC Group Berhad stock attractive at the current price?
The data as of Nov 4, 2026: price 0.2650 MYR, calculated fair value 0.4500 MYR (+70%), Quality Score 47/100, from 16 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 0256 calculated?
We run UMediC Group Berhad through 16 models from 6 families: Earnings-Based, Dividend Discount, Multiples, Asset-Based, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of 0.4500 MYR builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. UMediC Group Berhad currently trades 41% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of UMediC Group Berhad (0256)?
The closing price on Nov 6, 2026 was 0.2650 MYR. Our model-based fair value is 0.4500 MYR, about +70% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with UMediC Group Berhad right now?
The large discount to fair value meets weak quality (47/100). That raises the risk this is a value trap rather than a bargain. The price is below even our cautious bear case (0.3100 MYR). The market is more pessimistic than our downside scenario. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range (0.3100 MYR to 0.5700 MYR) leaves room in how you read the outcome.

Key figures of UMediC Group Berhad

How large is the market capitalisation of UMediC Group Berhad (0256)?
The market capitalisation of UMediC Group Berhad is 99.1M MYR (≈ $24.4M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of UMediC Group Berhad (0256)?
The price-to-sales ratio of UMediC Group Berhad is 1.69 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of UMediC Group Berhad (0256)?
Earnings per share at UMediC Group Berhad are 0.0206 MYR (price ÷ EPS = P/E 12.9). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of UMediC Group Berhad (0256)?
The dividend yield of UMediC Group Berhad is 1.1% (payout 14.6%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of UMediC Group Berhad (0256)?
The net margin of UMediC Group Berhad is 13.2% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of UMediC Group Berhad (0256)?
The return on equity (ROE) of UMediC Group Berhad is 9.6% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of UMediC Group Berhad (0256)?
On an EBIT basis the return on assets of UMediC Group Berhad is 12.1% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of UMediC Group Berhad (0256)?
The operating margin of UMediC Group Berhad is 14.3% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at UMediC Group Berhad (0256)?
Revenue at UMediC Group Berhad is growing +52.0% versus a year earlier (3y avg +8.9%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at UMediC Group Berhad (0256)?
Earnings per share at UMediC Group Berhad are growing −18.8% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does UMediC Group Berhad (0256) generate?
The free cash flow of UMediC Group Berhad is −16.6M MYR (fiscal year 2026). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does UMediC Group Berhad (0256) carry?
The net debt of UMediC Group Berhad is 1.3M MYR (fiscal year 2026). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch UMediC Group Berhad in the live analysis

One click puts UMediC Group Berhad on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.